Lucid Diagnostics Inc. (LUCD) News
Filter LUCD News Items
LUCD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
LUCD News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest LUCD News From Around the Web
Below are the latest news stories about LUCID DIAGNOSTICS INC that investors may wish to consider to help them evaluate LUCD as an investment opportunity.
Lucid Inks New Partnership With VITALExam: Stock to Gain?LUCD collaborates with VITALExam to enhance access to the EsoGuard Esophageal DNA Test. The partnership launches a fully contracted testing event for Tuscaloosa firefighters. |
Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RuleLucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it had received written notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") that the Company was eligible for a 180-day extension to regain compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule"). The Comp |
Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for FirefightersLucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has entered into a strategic partnership with VITALExam LLC (VITALExam), a comprehensive medical care provider for first responders founded by Chief Executive Officer Marci Vitale, DNP, FNP-BC, AGACNP-BC, to enhance access to Lucid's EsoGuard® Esophageal DNA Test for firefighters at risk for esoph |
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed PublicationLucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the manuscript for its CLinical Utility of EsoGuard (CLUE) study has been accepted for publication in the peer-reviewed journal Medicina. This is the fourth peer-reviewed publication presenting outstanding clinical utility data for the EsoGuard® Esophageal DNA Test. In addition to demonstrating near- |
Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term MilestonesLucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the successful completion of a convertible debt refinancing transaction that strengthens its balance sheet and extends its cash runway past near-term reimbursement milestones. Lucid issued five-year convertible notes to long-term equity shareholders in an aggregate principal amount of $21.95 million. A to |
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA TestLucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has submitted its complete clinical evidence package for its EsoGuard® Esophageal DNA Test in support of a Request for Reconsideration of Local Coverage Determination (LCD) L39256 "MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia" to Molecular Di |
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumLucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that company management will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 21, 2024 at 1:30 p.m. ET. |
Q3 2024 PAVmed Inc Earnings CallQ3 2024 PAVmed Inc Earnings Call |
PAVmed Inc (PAVM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic RestructuringPAVmed Inc (PAVM) reports a transformative quarter with a 20% revenue increase and key financial maneuvers to strengthen its corporate structure. |
PAVmed Provides Business Update and Third Quarter 2024 Financial ResultsPAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and presented financial results for the Company for the three months ended September 30, 2024. |